Curis Hit With Nasdaq Delisting Determination After Sub-$1 Bid
CRIS has more than doubled off its 52-week low of $0.325.
Summary
Curis received a Nasdaq delisting determination on November 2, 2026 after 30 days below the $1.00 bid threshold, and its July reverse split blocks the standard compliance period. The company will request a Panel hearing, which stays delisting action but offers no guarantee.
Key Events · Legal and Risk Events · CRIS
-
Nasdaq Issues Delisting Determination
On November 2, 2026, Nasdaq's Listing Qualifications Staff notified Curis that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, a violation of Listing Rule 5550(a)(2).
-
Reverse Split Blocks Cure Period
Because Curis effected a 1-for-20 reverse stock split on July 6, 2026, Rule 5810(c)(3)(A)(iv) makes it ineligible for any compliance period to regain the $1.00 bid.
-
Panel Monitor Already In Place
A July 24, 2026 Nasdaq Hearings Panel decision placed Curis under a one-year Discretionary Panel Monitor under Rule 5815(d)(4)(A).
-
Hearing Request Would Stay Delisting
Curis intends to timely request a new hearing before the initial or a newly convened Panel, which stays further delisting actions; the filing states there is no assurance the appeal succeeds or that the company remains listed.
Analysis · CRIS · Life Sciences
Nasdaq staff has formally moved to delist Curis, citing 30 straight business days of sub-$1.00 closes, and the July 6, 2026 1-for-20 reverse split disqualifies the company from the usual six-month cure period. That removes the ordinary path to fix the bid price, leaving a new hearing before a Nasdaq Panel as the only route; the company says it will request one, which would pause any delisting action. The appeal is not assured. This lands on a company that already told investors in its Q2 2026 10-Q there is substantial doubt about its ability to continue as a going concern with cash runway only into Q4 2026, and that raised $8.5 million in an October private placement at $0.51 per share. A delisting would push CRIS off Nasdaq Capital Market, hurting liquidity and the ability to raise the capital it needs to keep operating.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.33 to $29.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.